Developing Story: From CLEOPATRA to Life on Enhertu – HER2+ MBC with Dr. Erika Hamilton & Dr. Sarah Premji
wenty-five years ago, HER2-positive breast cancer meant a two-year death sentence. Today, patients are living 12+ years on first-line treatment—and some are being cured.
In this deep dive, host Victoria Goldberg (living with metastatic HER2+ cancer for 12 years) and leading oncologists Dr. Erika Hamilton and Dr. Sarah Premji unpack the drugs, trials, and real-world strategies transforming one of cancer's most feared diagnoses into its greatest success story.
From CLEOPATRA's game-changing 16-month survival boost to antibody-drug conjugates that deliver chemotherapy straight to cancer cells, learn how precision medicine is rewriting the rules—and what patients need to know about side effects, sequencing, and hope.
Front Row: SABCS 2025 Insights with Dr. Francisco Esteva
Join host Victoria Goldberg and Dr. Francisco Esteva as they break down the groundbreaking research from the San Antonio Breast Cancer Symposium 2025. Discover the latest advances in metastatic breast cancer treatment, including new first-line therapies for HER2-positive disease with 40-month progression-free survival, oral SERDs revolutionizing hormone receptor-positive treatment, and antibody drug conjugates transforming triple-negative breast cancer care. Dr. Esteva shares expert insights on brain metastasis prevention, liquid biopsy-guided therapy switching, and how artificial intelligence is reshaping oncology. Whether you're a patient, caregiver, or healthcare professional, this episode offers hope and practical information about the cutting-edge treatments available in 2026.